The original FLOW (Evaluate Renal Function with Semaglutide Once Weekly) trial in 3533 patients with type 2 diabetes and CKD found subcutaneous semaglutide 1 mg once weekly reduced the risk of the primary kidney endpoint (at least a 50% decline of estimated glomerular filtration rate, kidney failure or kidney or cardiovascular death) by 24% and all-cause death by 20%
Munro JF, MacCuish AC, Wilson EM, Duncan LJP
Ultra-thin serum sheets that melt with a spritz of mist, infused with glutathione to hydrate and enhance the skins natural radiance
These medications are specifically engineered to target hormonal pathways in the brain and gut that regulate hunger, insulin, and metabolism
He adds that SURMOUNT-MMO is also worth watching for a number of its secondary outcomes, including time to onset of type 2 diabetes, renal death or end-stage renal disease, and a variety of quality-of-life measures